Oncolytics Biotech Starts Patient Treatment in UK Phase I Cancer Trial Investigating Systemic Delivery of REOLYSIN(R)
This clinical trial is an open-label, dose-escalation Phase I study in which REOLYSIN(R) will be administered intravenously to patients diagnosed with advanced or metastatic solid tumours that are refractory to standard therapy (have not responded) or for which no curative standard therapy exists. The primary objective of the study is to determine the maximum tolerated dose (MTD), dose limiting toxicity (DLT) and safety profile of REOLYSIN(R). Secondary objectives include the evaluation of viral replication, immune response to the virus and any evidence of antitumour activity. The enrolment in this study is expected to be up to forty evaluable patients and will depend upon the number of dose levels tested. The principal investigator for the study is Dr. J. de Bono of the Royal Marsden Hospital.
Most read news
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.